Acetylshikonin stimulates glucose uptake in L6 myotubes via a PLC-β3/PKCδ-dependent pathway

Biomed Pharmacother. 2019 Apr:112:108588. doi: 10.1016/j.biopha.2019.01.049. Epub 2019 Feb 16.

Abstract

Acetylshikonin, a naphthoquinone derivative derived from Lithospermum erythrorhizon, has been shown to have various pharmacological activities; however, its effect on diabetes has rarely been reported. We investigated the hypoglycemic effect of acetylshikonin and found that it decreased blood glucose to a greater extent than insulin and improved glucose tolerance in mice. It also increased glucose uptake in L6 myotubes by inducing the expression and translocation of glucose transporter 4 via decomposition of phosphatidylinositol, increased generation of diacylglycerol, and activation of protein kinase C delta cascades; this is an insulin-, reactive oxygen species-, and AMP-activated protein kinase-independent pathway for glucose uptake. Our findings highlight the antidiabetic potential of acetylshikonin via a possible novel pathway for glucose uptake in L6 myotubes.

Keywords: Acetylshikonin; Diabetes; Glucose uptake; Phosphatidylinositol; Protein kinase C delta.

MeSH terms

  • Animals
  • Anthraquinones / pharmacology*
  • Cells, Cultured
  • Dose-Response Relationship, Drug
  • Glucose / agonists
  • Glucose / metabolism*
  • Mice
  • Muscle Fibers, Skeletal / drug effects*
  • Muscle Fibers, Skeletal / metabolism*
  • Phospholipase C beta / metabolism*
  • Protein Kinase C-delta / metabolism*
  • Random Allocation
  • Rats

Substances

  • Anthraquinones
  • Protein Kinase C-delta
  • Phospholipase C beta
  • Plcb3 protein, mouse
  • Glucose
  • acetylshikonin